RxDoctor Payments Data

Rami Eid, MD

Gastroenterology · Richmond, VANPI 1144217050

Payments from drug & device makers

$4,738in general payments, 2019–2025

Across 222 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$404
  • Bristol Myers Squibb$211
  • QOL Medical, LLC$198
  • Conmed Corporation$166
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$163
  • plus $605 from 14 others

What the payments were for

  • Food & beverage$4,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,738 in reported general payments places this provider in the 50th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$115,214
Medicare patients
484
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$34,603
MounjaroTirzepatide14$14,329
LinzessLinaclotide13$10,225
Mesalamine ErMesalamine16$10,217
Mesalamine31$8,881
Pantoprazole Sodium349$5,302
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates60$4,018
Colestipol Hcl44$3,346
Lubiprostone16$1,951
Esomeprazole Magnesium40$1,413
Omeprazole116$1,262
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl80$1,226
Sucralfate24$1,024
Famotidine79$772
Lansoprazole20$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,991$44,82724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →